Valley Fever
FIP
Treatments
Trials
Store
Insider
Events
Valley Fever
FIP
Treatments
Biologics
Discovery
Trials
Store
Cart
Insider
Learn
Events
About
Investor Relations
Company Profile
Leadership and Governance
Social Responsibility
Investor FAQ
Contact
Dr. Antonella Borgatti
Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma
_KPT-335_(verdinexor)_in_dogs_with_lymphoma.pdf?width=2048&quality=auto&auto=webp){kind=spacer}